Grufity logo
Grufity logo
NEXI

NEXI - NexImmune, Inc. Stock Price, Fair Value and News

00
Delayed as of 13 Jul 2026, 04:00 pm ET

Price Targets

NEXI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NEXI Price Action

NEXI RSI Chart

NEXI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NEXI Valuation

Market Cap

0

Price/Earnings (Trailing)

0

Price/Free Cashflow

0

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

NEXI Fundamentals

NEXI Earnings

NEXI Profitability

Free Cashflow Yield

0%

NEXI Investor Care

Revenue & Growth

How NexImmune, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

About NexImmune, Inc.

NEXI
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEneximmune.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES50

NexImmune, Inc. Frequently Asked Questions

NEXI is the stock ticker symbol of NexImmune, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 10 2026, market cap of NexImmune, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.